New Treatment to Delay Type 1 Diabetes
On November 17,2022 the FDA approved a new treatment to delay the onset of type 1 Diabetes in those over 8 years of age and those who are at high risk for developing diabetes. The drug is called teplizumab and its an anti-CD3 monoclonal antibody.
Those that qualify need to have positive diabetes autoimmune antibodies and start to show glucose irregularities without overt symptoms. This is referred to stage 2 diabetes. To learn more about the other stages click on this hyperlink https://www.trialnet.org/t1d-facts
The drug interferes with autoimmune destruction of the pancreatic cells that make insulin. Insulin is needed to keep blood sugars tightly controlled.
Though this is not a cure for diabetes, its a huge milestone in the treatment/care of diabetes and it could delay the onset of type 1 diabetes by 2 years.
https://www.trialnet.org/our-research/completed-studies/teplizumab